Χώρα: Ηνωμένες Πολιτείες
Γλώσσα: Αγγλικά
Πηγή: NLM (National Library of Medicine)
rivastigmine tartrate (UNII: 9IY2357JPE) (rivastigmine - UNII:PKI06M3IW0)
Dr. Reddy's Laboratories Limited
rivastigmine tartrate
rivastigmine 1.5 mg
ORAL
PRESCRIPTION DRUG
Rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type (AD). Rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PD). Rivastigmine tartrate is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see Description (11) ] - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see Warnings and Precautions (5.2) ] Isolated cases of generalized skin reactions have been described in postmarketing experience [see Adverse Reactions (6.2) ]. Risk Summary There are no adequate data on the developmental risks associated with the use of rivastigmine tartrate in pregnant women. In animals, no adverse effects on embryo-fetal development were observed at oral doses 2 to 4 times the
Rivastigmine tartrate capsules USP, equivalent to 1.5 mg, 3 mg, 4.5 mg or 6 mg of rivastigmine base are available as follows: Rivastigmine tartrate capsules USP, 1.5 mg are white to off-white powder filled in size ‘2’ hard gelatin capsules with light tan opaque color cap and light tan opaque color body, imprinted ‘RDY” on cap and ‘352’ on body with black ink and are supplied in bottles of 30, 60, 100 and 500. Bottles of 30 NDC 55111-352-30 Bottles of 60 NDC 55111-352-60 Bottles of 100 NDC 55111-352-01 Bottles of 500 NDC 55111-352-05 Rivastigmine tartrate capsules USP, 3 mg are white to off-white powder filled in size ‘2’ hard gelatin capsules with brown opaque color cap and brown opaque color body, imprinted ‘RDY’ on cap and ‘353’ on body with black ink and are supplied in bottles of 30, 60, 100 and 500. Bottles of 30 NDC 55111-353-30 Bottles of 60 NDC 55111-353-60 Bottles of 100 NDC 55111-353-01 Bottles of 500 NDC 55111-353-05 Rivastigmine tartrate capsules USP, 4.5 mg are white to off-white powder filled in size ‘2’ hard gelatin capsules with swedish orange opaque color cap and swedish orange opaque color body, imprinted 'RDY' on cap and '354' on body with black ink and are supplied in bottles of 30, 60, 100 and 500. Bottles of 30 NDC 55111-354-30 Bottles of 60 NDC 55111-354-60 Bottles of 100 NDC 55111-354-01 Bottles of 500 NDC 55111-354-05 Rivastigmine tartrate capsules USP, 6 mg are white to off-white powder filled in size ‘2’ hard gelatin capsules with swedish orange opaque color cap and brown opaque color body, imprinted ‘RDY’ on cap and ‘355’ on body with black ink and are supplied in bottles of 30, 60, 100 and 500. Bottles of 30 NDC 55111-355-30 Bottles of 60 NDC 55111-355-60 Bottles of 100 NDC 55111-355-01 Bottles of 500 NDC 55111-355-05 Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].
Abbreviated New Drug Application
RIVASTIGMINE TARTRATE- RIVASTIGMINE TARTRATE CAPSULE DR. REDDY'S LABORATORIES LIMITED ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE RIVASTIGMINE TARTRATE CAPSULES SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR RIVASTIGMINE TARTRATE CAPSULES. RIVASTIGMINE TARTRATE CAPSULES, FOR ORAL USE INITIAL U.S. APPROVAL: 2000 INDICATIONS AND USAGE Rivastigmine tartrate capsule is an acetylcholinesterase inhibitor indicated for treatment of: Mild-to-moderate dementia of the Alzheimer’s type (AD) (1.1) Mild-to-moderate dementia associated with Parkinson’s disease (PD) (1.2) DOSAGE AND ADMINISTRATION Alzheimer’s Disease (2.1): Initial Dose: Initiate treatment with 1.5 mg twice a day. Dose Titration: After a minimum of 2 weeks, if tolerated, increase dose to 3 mg twice a day and further to 4.5 mg twice a day and 6 mg twice a day if tolerated with a minimum of 2 weeks at each dose Parkinson’s Disease Dementia (PDD) (2.2): Initial Dose: Initiate treatment with 1.5 mg twice a day. Dose Titration: After a minimum of 4 weeks, if tolerated, increase dose to 3 mg twice a day and further to 4.5 mg twice a day and 6 mg twice a day if tolerated with a minimum of 4 weeks at each dose. Rivastigmine tartrate capsule should be taken with meals in divided doses in the morning and evening (2.1, 2.2). DOSAGE FORMS AND STRENGTHS Capsules: 1.5 mg, 3 mg, 4.5 mg, or 6 mg (3.1) CONTRAINDICATIONS Known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation. (4) History of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing. (4, 5.2) WARNINGS AND PRECAUTIONS Gastrointestinal adverse reactions may include significant nausea, vomiting, diarrhea, anorexia/decreased appetite, and weight loss, and may necessitate treatment interruption. Dehydration may result from prolonged vomiting or diarrhea and can be associated with serious Διαβάστε το πλήρες έγγραφο